Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review

International Journal of Cancer

Volumn 128, Issue 5, 2011, Pages 1080-1094

  Shima, Kaori ^a   Nosho, Katsuhiko ^a   Baba, Yoshifumi ^a   Cantor, Mami ^a   Meyerhardt, Jeffrey A ^a   Giovannucci, Edward L ^b,c   Fuchs, Charles S ^a,b   Ogino, Shuji ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CDKN2A; clinical outcome; colon cancer; epigenetics; hypermethylation; prognosis; survival

Indexed keywords

B RAF KINASE; BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; FATTY ACID SYNTHASE; K RAS PROTEIN; NEUROGENIN 1; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CACNA1G; PROTEIN CRABP1; PROTEIN MLH1; PROTEIN P53; SOMATOMEDIN B RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER SURVIVAL; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

AGED; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES;

EID: 78650733422     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25432     Document Type: Review

References (61)

1. Collado M, Blasco MA, Serrano M,. Cellular senescence in cancer and aging. Cell 2007; 130: 223-33.
2. Liu Y, Sharpless NE,. Tumor suppressor mechanisms in immune aging. Curr Opin Immunol 2009; 21: 431-9.
3. Esteller M, Corn PG, Baylin SB, Herman JG,. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9.
4. Paya A, Alenda C, Perez-Carbonell L, Rojas E, Soto JL, Guillen C, Castillejo A, Barbera VM, Carrato A, Castells A, Llor X, Andreu M, et al. Utility of p16 immunohistochemistry for the identification of Lynch syndrome. Clin Cancer Res 2009; 15: 3156-62.
5. Gibson SL, Boquoi A, Chen T, Sharpless NE, Brensinger C, Enders GH,. p16(Ink4a) inhibits histologic progression and angiogenic signaling in min colon tumors. Cancer Biol Ther 2005; 4: 1389-94.
6. Furth EE, Gustafson KS, Dai CY, Gibson SL, Menard-Katcher P, Chen T, Koh J, Enders GH,. Induction of the tumor-suppressor p16(INK4a) within regenerative epithelial crypts in ulcerative colitis. Neoplasia 2006; 8: 429-36.
7. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML,. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129: 837-45.
8. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F,. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68: 8541-6.
9. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008; 3: e3698.
10. Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, Rashid A, Hamanaka Y, et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res 2008; 14: 2560-9.
11. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP,. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-6. (Pubitemid 29354851)
12. Teodoridis JM, Hardie C, Brown R,. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008; 268: 177-86.
13. Kim J, Shin S, Kwon H, Cho N, Kang GH,. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchow Arch 2009; 455: 485-94.
14. Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Wu MS, Wang SM, Lin JT, Cheng AL,. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology 1999; 57: 149-56.
15. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA,. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299-304.
16. Norrie MW, Hawkins NJ, Todd AV, Meagher AP, O'Connor TW, Ward RL,. Inactivation of p16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. J Surg Oncol 2003; 84: 143-50.
17. Maeda K, Kawakami K, Ishida Y, Ishiguro K, Omura K, Watanabe G,. Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep 2003; 10: 935-8.
18. Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, Dent OF, Dhillon VS, Trent RJ, Chapuis PH, Bokey EL,. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005; 23: 2318-24.
19. Sanz-Casla MT, Maestro ML, Vidaurreta M, Maestro C, Arroyo M, Cerdan J,. p16 Gene methylation in colorectal tumors: correlation with clinicopathological features and prognostic value. Dig Dis 2005; 23: 151-5.
20. Ishiguro A, Takahata T, Saito M, Yoshiya G, Tamura Y, Sasaki M, Munakata A,. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol 2006; 21: 1334-9.
21. Shen L, Catalano PJ, Benson AB, 3rd, O'Dwyer P, Hamilton SR, Issa JP,. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007; 13: 6093-8.
22. Krtolica K, Krajnovic M, Usaj-Knezevic S, Babic D, Jovanovic D, Dimitrijevic B,. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol 2007; 13: 1187-94.
23. Mitomi H, Fukui N, Tanaka N, Kanazawa H, Saito T, Matsuoka T, Yao T,. Aberrant p16(INK4a) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clin Oncol 2010; 136: 323-31.
24. Kim JC, Choi JS, Roh SA, Cho DH, Kim TW, Kim YS,. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol, in press.
25. Zhao P, Hu YC, Talbot IC,. Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 2003; 9: 2202-6.
26. Cui X, Shirai Y, Wakai T, Yokoyama N, Hirano S, Hatakeyama K,. Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 2004; 35: 1189-95.
27. Gonzalez-Quevedo R, Garcia-Aranda C, Moran A, De Juan C, Sanchez-Pernaute A, Torres A, Diaz-Rubio E, Balibrea JL, Benito M, Iniesta P,. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. Int J Oncol 2004; 24: 349-55.
28. Lyall MS, Dundas SR, Curran S, Murray GI,. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006; 12: 1184-91.
29. Lam AK, Ong K, Giv MJ, Ho YH,. p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology 2008; 40: 580-5.
30. Wassermann S, Scheel SK, Hiendlmeyer E, Palmqvist R, Horst D, Hlubek F, Haynl A, Kriegl L, Reu S, Merkel S, Brabletz T, Kirchner T, et al. p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors. Gastroenterology 2009; 136: 196-205.
31. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ,. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003; 21: 3729-36.
32. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS,. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-6.
33. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B,. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9: 2898-903.
34. Chan AT, Ogino S, Fuchs CS,. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-42.
35. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS,. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007; 9: 305-14.
36. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S,. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008; 10: 534-41.
37. Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS,. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008; 122: 2767-73. (Pubitemid 351631379)
38. Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS,. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006; 210: 147-54. (Pubitemid 44463929)
39. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS,. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol 2007; 38: 585-92.
40. Nosho K, Kawasaki T, Chan AT, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, Ogino S,. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology 2008; 53: 588-98.
41. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, Ogino S,. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 2007; 9: 569-77.
42. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS,. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006; 8: 458-64.
43. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS,. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol 2007; 38: 842-9.
44. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS,. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005; 7: 413-21.
45. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS,. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006; 8: 582-8.
46. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS,. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006; 19: 59-68.
47. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS,. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006; 8: 209-17.
48. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-93.
49. Irahara N, Nosho K, Baba Y, Shima K, Lindeman NI, Hazra A, Schernhammer ES, Hunter DJ, Fuchs CS, Ogino S,. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn 2010; 12: 177-83.
50. Wettergren Y, Odin E, Nilsson S, Carlsson G, Gustavsson B,. p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer. Mol Med 2008; 14: 412-21.
51. Spain SL, Cazier JB, Houlston R, Carvajal-Carmona L, Tomlinson I,. Colorectal cancer risk is not associated with increased levels of homozygosity in a population from the United Kingdom. Cancer Res 2009; 69: 7422-9.
52. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A,. Clinico-pathological and protein characterization of BRAF and K-RAS mutated colorectal cancer and implications for prognosis. Int J Cancer 2010; 127: 367-80.
53. Iacopetta B, Heyworth J, Girschik J, Grieu F, Clayforth C, Fritschi L,. The MTHFR C677T and DeltaDNMT3B C-149T polymorphisms confer different risks for right- and left-sided colorectal cancer. Int J Cancer 2009; 125: 84-90.
54. Strater J, Herter I, Merkel G, Hinz U, Weitz J, Moller P,. Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: Caspase-8 and caspase-9 is associated with poor prognosis. Int J Cancer, in press.
55. Rojas A, Meherem S, Kim YH, Washington MK, Willis JE, Markowitz SD, Grady WM,. The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. Int J Cancer 2008; 123: 14-21.
56. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lievre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008; 122: 2255-9.
57. Kets CM, van Krieken JH, van Erp PE, Feuth T, Jacobs YH, Brunner HG, Ligtenberg MJ, Hoogerbrugge N,. Is early-onset microsatellite and chromosomally stable colorectal cancer a hallmark of a genetic susceptibility syndrome? Int J Cancer 2008; 122: 796-801.
58. Ogino S, Goel A,. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008; 10: 13-27.
59. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS,. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008; 100: 1734-8.
60. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74.
61. Popat S, Hubner R, Houlston RS,. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18.